Journal of Evidence-Based Dental Practice
Volume 9, Issue 1 , Pages 13-15 , March 2009

Low Incidence of Osteonecrosis of the Jaw in Postmenopausal Women With Osteoporosis Taking Zoledronic Acid Once Yearly

References 

  1. Black D, Delmas P, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–1822
  2. Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement. 2000;17(1):1–45
  3. Edwards B, Migliorati C. Osteoporosis and its implications for dental patients. J Am Dent Assoc. 2008;139(5):545–552quiz 625-6
  4. Liberman U, Weiss S, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995;333(22):1437–1443
  5. Harris S, Watts N, Genant H, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282(14):1344–1352
  6. Neer R, Arnaud C, Zanchetta J, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–1441
  7. Goss A. Bisphosphonate-associated osteonecrosis of the jaws. Climacteric. 2007;10(1):5–8
  8. Marx R. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115–1117
  9. Migliorati C. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol. 2003;21(22):4253–4254
  10. Ruggiero S, Mehrotra B, Rosenberg T, Engroff S. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62(5):527–534
  11. Migliorati C, Casiglia J, Epstein J, Jacobsen P, Siegel M, Woo S. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc. 2005;136(12):1658–1668
  12. Migliorati C. Bisphosphonate-associated oral osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;99(2):135
  13. Smith M. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rev. 2005;31(Suppl 3):19–25
  14. Woo S, Hellstein J, Kalmar J. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144(10):753–761
  15. Grbic J, Landesberg R, Lin S, et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc. 2008;139(1):32–40
  16. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65(3):369–376
  17. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc. 2006;137(8):1144–1150Updated Aug 2008, Available at: http://www.ada.org/prof/resources/topics/osteonecrosis.asp. Accessed November 24, 2008.

PII: S1532-3382(08)00226-1

doi: 10.1016/j.jebdp.2008.12.014

Journal of Evidence-Based Dental Practice
Volume 9, Issue 1 , Pages 13-15 , March 2009

Article Tools